Metabolomics of Dynamic Changes in Insulin Resistance Before and After Exercise in PCOS

Anna Halama†, Myint Myint Aye†, Soha R. Dargham3, Michal Kulinski4, Karsten Suhre1 and Stephen L. Atkin5*

1 Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Doha, Qatar, 2 Department of Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, United Kingdom, 3 Infectious Disease Epidemiology Group, Weill Cornell Medicine, Doha, Qatar, 4 Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar, 5 Weill Cornell Medicine-Qatar, Doha, Qatar

Background: Plasma elevated levels of branched chain amino acids (BCAA) and aromatic amino acids (AAA) have been associated with obesity and insulin resistance, but their relationship to stimulated insulin resistance (IR) in PCOS and in response to exercise is unknown. Indeed, it is unknown whether the mechanism of IR in PCOS is mediated through changes in the metabolome.

Methods: Twelve women with polycystic ovary syndrome (PCOS) and ten age and body mass index matched controls completed an 8 week supervised exercise program at 60% maximal oxygen consumption. Before and after the exercise program, all participants underwent maximal IR stimulation with intralipid infusions followed by insulin sensitivity (IS) measurement by hyperinsulinaemic euglycaemic clamps. Amino acid profiles and metabolites were taken at baseline and at maximal insulin resistance stimulation before and after the exercise program.

Results: At baseline, PCOS subjects showed increased leucine/isoleucine, glutamate, methionine, ornithine, phenylalanine, tyrosine and proline (p < 0.05) that, following exercise, did not differ from controls. While comparing within the groups, no significant changes in the amino acid levels before and after exercise were observed. Exercise improved VO2 max (p < 0.01) but did not alter weight. Amino acid profiles were unaffected by an acute increase in IR induced by the lipid infusion. IS was lower in PCOS (p < 0.001) and was further decreased by the lipid infusion in both PCOS and controls. Although, exercise improved IS in both PCOS and in controls, the IS remained compromised in PCOS.

Conclusion: The baseline amino acid profile in PCOS reflected that seen in obese subjects and differed to controls. After exercise, and despite no change in weight in either group, there were no differences in the amino acid profile between PCOS and controls. This shows that exercise may normalize the amino acid metabolome, irrespective of weight.

Keywords: insulin resistance, intralipid, exercise, PCOS, metabolomics, amino acid
INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders, affecting up to 20% of reproductive-aged women (1, 2). There are three available diagnostic criteria for PCOS; the National Institute of Health (NIH) (3), ESHRE/ASRM Rotterdam consensus criteria (4) and the androgen excess and PCOS society (AES) (5). However, by any of the diagnostic criteria, PCOS is associated with metabolic features commonly related to lower insulin sensitivity (IS) that is contributed to by an increased BMI in women with PCOS compared to those without PCOS (6); PCOS subjects that were overweight showed moderately lower IS compared with lean PCOS (7). This is reflected in an increased prevalence of gestational diabetes, impaired glucose tolerance and type 2 diabetes (5-fold in Asia, 4-fold in the Americas, and 3-fold in Europe) in PCOS irrespective of age, with risk independent of, though exacerbated by, obesity (2).

The strategies addressing health issues in women with PCOS mainly focus on the reproductive dysfunction and compromised sensitivity to insulin [insulin resistance (IR)] (8). It has been shown that physical activity significantly reduced IR and improved lipid homeostasis in obese individuals at risk of developing type 2 diabetes (T2D) (9). There is also increasing evidence suggesting that moderate exercises could be considered as a strategy to reduce IR in PCOS patients as a significant improvement in IS (23–30%) was observed in several studies involving PCOS patients before and after exercise (10–12). Normalization of insulin responses in patients is crucial for metabolic homeostasis and thus body function. Moderate intensity exercise increases mitochondrial fatty acid oxidation and decreases diacylglycerol (DAG) and ceramide content of skeletal muscle in obese subjects (13); remarkably, a single session of exercise completely normalized fatty acid accumulation and reversed fatty acid-induced IR in healthy subjects (14).

The bioanalytical discipline of metabolomics measures the small molecules (metabolites) that are mediators and products of metabolism that has been shown to provide further insights into the field of complex diseases (15). For instance, metabolomics based studies have revealed an association between IR and deregulated metabolism of aromatic amino acids (AAA) such as phenylalanine and tyrosine (16) as well as branched chain amino acids (BCAA) (isoleucine, valine and leucine), and different carnitines (16–18). The interplay between BCAA and lipids was suggested as a contributor to the development of IR in obese individuals (19). Thus, it could be hypothesize that the moderate exercise might improve IR and thus overall body metabolism in PCOS patients.

The complex metabolic pathways underlying PCOS are not well understood though the few studies focused on describing deregulated carbohydrate, fat and protein metabolism have been conducted (20–24). However, to the best of our knowledge the impact of moderate exercise on overall body metabolism in PCOS patients, has not been investigated. Given that IR was shown to be associated with deregulated BCAA and AA metabolism (17), we hypothesized that moderate exercise would decrease the IR in PCOS and thus improve the overall metabolic status.

Lipid infusion delivers a dynamic and maximal measure of IR, and the gold standard for IR measurement is the hyperglycemic glucose clamp method to determine IR change with an intervention. An acute fat load orally or intravenously results in an acute rise in DAG in the muscle that subsequently induces insulin resistance by reducing non-oxidative glucose disposal through protein kinase C theta (PKCθ) activation (25).

The aim of our study was to investigate the overall metabolic homeostasis after 8 weeks of moderate exercise in women with and without PCOS in the context of IR. The metabolic parameters were investigated before and after exercise under conditions of 1, hyperinsulinaemic euglycaemic clamp and saline infusions as well as 2, hyperinsulinaemic euglycaemic clamp and intralipid infusions to exaggerate the metabolic responses.

SUBJECTS AND METHODS

This study was approved by the Leeds Central Research Ethics Committee, Yorkshire and Humber REC no. 10/H1313/44 and all subjects gave their written informed consent to participate in the study. Subjects with PCOS were recruited from endocrine clinics, and normal female controls were recruited through advertisements at a local university and in the hospital newsletters. PCOS was diagnosed based on the presence of two out of three criteria; oligomenorrhea, clinical or biochemical hyperandrogenism and polycystic ovaries on ultrasound after exclusion of other endocrine causes of hyperandrogenism according to the Rotterdam criteria (4); however, all PCOS women included in the study fulfilled all 3 criteria. All the subjects gave their informed consent to participate in the study. They were all non-smokers, took no regular medications, had no concurrent illness and had had no regular exercise prior to the study. All women had a pregnancy test prior to their inclusion in the study. Subjects who were diagnosed with impaired glucose tolerance at screening oral glucose tolerance test were excluded. Subjects were requested not to modify other aspects of their lifestyle, including their dietary pattern, during the study period. All the subjects had anthropometric measurements and fasting blood sampling.

To assess maximal stimulation of insulin resistance, each subject had either 3 h saline or intralipid infusions at baseline; this was immediately followed by hyperinsulinaemic euglycaemic clamps with continuance of the saline or lipid infusion to assess insulin sensitivity. Normal control women had the initial clamp in the first week of their menstrual cycle, whilst PCOS women were clamped after 6 weeks of amenorrhea. These tests were repeated after completion of an 8 week moderate intensity exercise program.

Hyperinsulinaemic Euglycaemic Clamps

Following a 12 h overnight fast, participants underwent a hyperinsulinaemic euglycaemic clamp that measured insulin sensitivity whilst receiving an infusion of normal saline on the first occasion, followed by a second intralipid infusion within a week. An 18 gauge intravenous cannula was inserted into an antecubital vein to administer test infusions and a retrograde cannula was inserted into the dorsal hand vein on the
contralateral hand. This hand was heated (60°C) to arterialize venous blood for the measurement of blood glucose. On the lipid infusion day, an additional cannula was placed in the contralateral antecubital vein for the lipid emulsion. After fasted blood samples were taken, either normal saline 1.5 mL/min or 20% intralipid 1.5 mL/min, along with unfractionated heparin sodium 0.3 unit/kg/min, was infused for 5 h. At 180 min, a 2 h hyperinsulinaemic euglycaemic clamp was started using intravenous soluble insulin (Humulin S, Eli Lilly and Co., Indianapolis, IN) at a rate of 80 mU/m² surface area/min for the first 20 min followed by a constant rate of 40 mU/m² surface area/min for the remaining 100 min. Plasma glucose was clamped at 5.0 mmol/L with a variable infusion rate of 20% dextrose, adjusted relative to arterialized glucose measurements undertaken every 5 min. Endogenous glucose production was more than 90% suppressed by an acute rise of insulin with the primed insulin infusion (26). The rate of insulin stimulated glucose disposal was based on total body weight (mg/kg/min) (M value), a measure of insulin sensitivity, was calculated from the mean of the five 20 min periods from 20–120 min during the clamp using the Defronzo method (27). Blood samples were taken at baseline and every hour for 5 h. These samples were centrifuged at 1500 G for 15 min at 4°C within 15 min of sampling, and then plasma and serum stored at −80°C until analysis.

Exercise Intervention
All participants underwent a structured supervised exercise program for a 1 h session, three times per week for 8 weeks in the sports laboratory at the Department of Sports, Health and Exercise Science, University of Hull. Moderate intensity exercise was defined as achieving a targeted heart rate equivalent to 60% of their baseline VO₂ max. Measurement of individualized VO₂ max was performed on a motorized treadmill starting with a warm up, then speeding to walking pace, then increasing every minute until the subject could not keep pace with the treadmill or became too tired to continue. Inspired and expired gas fractions, and heart rate were continuously monitored (28). All supervised exercise sessions achieved a targeted heart rate equivalent to 60% of their baseline VO₂ max. A mid-point reassessment was conducted to adjust the moderate intensity based on improvements in exercise capacity.

Biochemical Analysis
Serum insulin was assayed using a competitive chemiluminescent immunoassay (Euro/DPC, Llanberis, UK). Plasma glucose was measured using a Synchon LX 20 analyzer (Beckman-Coulter, High Wycombe, UK). Serum testosterone was measured by high performance liquid chromatography linked to tandem mass spectrometry (Waters Corporation, Manchester, UK) and sex hormone binding globulin (SHBG) was measured by immunometric assay with fluorescence detection on the DPC Immulite 2000 analyzer. The free androgen index (FAI) was obtained as the quotient 100° Testosterone/SHBG. Total cholesterol, triglycerides (TG), and high density lipoprotein cholesterol (HDL-c) were measured enzymatically using a Synchon LX20 analyzer (Beckman-Coulter, High Wycombe, UK). LDL-c was calculated using the Friedewald equation (29).

Metabolomics Measurements
For metabolomics analysis, samples were collected at (1) baseline; (2) 180 min after the saline/lipid infusion was started and (3) 120 min after the hyperinsulinaemic euglycaemic clamp was undertaken during the saline/lipid infusion (300 min from baseline). In total 288 samples were submitted out of which 7 were excluded due to insufficient volume of plasma. The remaining 281 samples consist of 131 controls and 150 PCOS.

The metabolites were measured in the Translational Research Institute (tTRI) at Hamad Bin Khalifa Medical City in Qatar using a targeted metabolomics assay from Biocrates Life Sciences AG (Innsbruck, Austria). The AbsoluteIDQ p150 kit assay enables quantification of up to 163 molecules including amino acids (AAs), phosphatidylcholines (PCs), lysoPCs, sphingomyelins (SM), carnitines (Ca), and hexoses (H), as previously described (30, 31). Briefly, sample preparation and measurement was conducted in a 96-well plate. Ten microliter of plasma was applied on the AbsoluteIDQ p150 kit plate consisting of filters with internal standards. The sample underwent drying under a nitrogen stream at room temperature (RT). Dried samples were derivatized with derivatization reagent (20 µL per well) containing 5% phenylisothiocyanate (PITC) followed by drying under a nitrogen stream at RT. The sample metabolite and internal standards were extracted with 300 µL of 5 mM ammonium acetate in methanol. Next, samples were filtered by centrifugation, and 20 µL of the flow-through was transferred to the fresh deep, 96-well plate and diluted with 380 µL of running solvent. The plate was covered with the silicone mat, mixed and placed in the autosampler Eksigent Ultra LC 100 (SCIEX). The metabolite detection was performed by FIA-MS/MS on an QTRAP®/Triple Quad™ 4500 LC-MS/MS system (SCIEX). Data evaluation was performed with MetIDQ software package. The complete analytical process was performed using the MetIQ software package, which is an integral part of the AbsoluteIDQ kit. The internal standards processed together with the samples were used as reference for the calculation of metabolite concentrations. The metabolite concentrations are reported in µmol/L. The leucine is depicted as xleucine and is representing the amount of leucine and isoleucine as they cannot be depicted as separate components within this method.

Data Analysis
Homeostatic model assessment of insulin resistance (HOMA-IR) was calculated by the formula: HOMA1-IR = fasting plasma insulin (µU/mL) x fasting plasma glucose (mmol/L)/22.5 (32).

Statistical analysis was performed using SPSS version 23.0 (SPSS Inc., Chicago, IL). Wilcoxon signed ranks test was applied to skewed variables that violated the assumptions of normality when tested with the Kolmogorov–Smirnov test, and paired sample t-test for normally distributed data within the group. Log transformation and then an unpaired t-test were undertaken on those data that were skewed. Data are presented as means ± SEMs. For all analyses, a two-tailed P ≤ 0.05 was considered to indicate statistical significance.
The Orthogonal Projections to Latent Structures (OPLS) analysis using time and saline/lipid challenge as phenotype was performed with SIMCA version 15 (Umetrics, Umeå, Sweden).

RESULTS

Twelve women with PCOS and ten healthy subjects, comparable in terms of age and BMI, completed the study. Baseline characteristics of the subjects are summarized in Table 1. Subjects with PCOS had a significantly larger waist hip ratio ($p = 0.02$), higher FAI ($p = 2.1 \times 10^{-3}$), and HOMA-IR ($p = 0.04$), as well as lower HDL-c, and sex hormone binding globulin (SHBG) ($p = 3.2 \times 10^{-3}$) than controls. PCOS subjects were less physically fit, as we observed significantly lower level of VO$_2$ max than in controls ($p = 5.6 \times 10^{-3}$).

Amino Acid Differences Between PCOS and Control

We quantified 163 metabolites after the lipid/saline challenges in PCOS and controls before and after exercise at three different time points [baseline (T1), 180 min after lipid/saline infusion (T2) and 120 min after the hyperinsulinaemic euglycaemic clamp was undertaken during the saline/lipid infusion (300 min from baseline) (T3)] using the targeted metabolomics assay based BioCrates AbsoluteIDQ p150 kit. The OPLS analysis revealed two clusters separating samples based on the lipid/saline infusion. Additionally, we observed clear separation between time point T2 and T3 (Supplementary Figure 1A). Long and short chain carnitines including octadecadienoylcarnitine (C18:2), hexadecadienoylcarnitine (C16:2), tetradecadienoylcarnitine (C14:2), 2-methylbutyrylcarnitine (C5), propionylocarnitine (C3), and acetyl carnitine (C2) together with amino acids (methionine, tryptophan, and phenylalanine) contributed mainly to the separation between lipid and saline infusion as shown by the loading plot of the OPLS (Supplementary Figure 1B). The separation between PCOS and control was not observed on the OPLS plot (Supplementary Figure 2).

We further evaluated levels of amino acids (arginine, glutamate, histidine, methionine, glycine, proline, serine, ornithine, phenylalanine, threonine, tryptophan, tyrosine, valine, xleucine), and carnitines (C2-carnitine, C3-carnitine, C5-carnitine).

At baseline, before the exercise PCOS subjects showed increased levels of xleucine, glutamate, methionine, ornithine, phenylalanine, tyrosine, and proline ($p < 0.05$) (Table 2). The level of acylcarnitines including C2-carnitine, C3-carnitine, and C5-carnitine were not significantly different between PCOS and control (Table 2). We further monitored whether lipid infusion is significantly impacting the selected metabolites. We observed that the acute IR induced by lipid infusion is resulting in significant decrease in tryptophan level and increase C2-carnitine level in both control and PCOS. Additionally in PCOS group lipid infusion resulted in significant decrease in the levels of methionine and phenylalanine (Supplementary Table 1). While comparing the metabolic profiles of PCOS and controls under lipid infusion before exercises we observed that only proline remained significantly lower in PCOS and the other metabolites, differentiating PCOS and controls at baseline were not significant (Table 3).

Next, we examined the impact of exercise on the metabolic profile at baseline and under acute IR induced by the lipid infusion. Although at the baseline there was no significant alteration before and after exercise in PCOS and control (Table 4), the significant differences in the levels of amino acids seen between PCOS and controls were no longer apparent after exercise (Table 2), suggesting normalization of the overall metabolic status. Under lipid infusion, we observed a significant decrease in the level of xleucine in control but not in PCOS subjects (Table 5), but there were no differences between control and PCOS subjects in the amino acid levels after exercise (Table 3).

Effect of Lipid on Insulin Resistance Before and After Exercise Intervention

During the saline infusion, PCOS subjects had a lower rate of insulin stimulated glucose disposal compared to controls (3.25 ± 0.76 vs. 4.8 ± 1.64 mg/kg/min; $p = 0.01$). Lipid caused a reduction in the insulin stimulated glucose disposal rate in PCOS from 3.25 ± 0.76 to 1.14 ± 0.78 mg/kg/min, $p = 1.9 \times 10^{-7}$, and in controls from 4.8 ± 1.64 to 2.5 ± 1.54 mg/kg/min, $p = 5.4 \times 10^{-4}$ (Supplementary Table 2). After 8 weeks of moderate intensity exercise, there were concomitant rises in insulin sensitivity in PCOS patients (glucose disposal mg/kg/min: PCOS pre-exercise 3.25 ± 0.76; post-exercise 3.95 ± 1.45; $p = 0.13$), and in controls (glucose disposal mg/kg/min: controls pre-exercise 4.8 ± 1.64; post-exercise 5.79 ± 1.74; $p < 0.02$). Exercise significantly improved lipid induced insulin resistance in both PCOS (glucose disposal mg/kg/min: PCOS pre-exercise 1.15 ± 0.79 vs. post-exercise

---

**Table 1 | Baseline characteristics of participants.**

|                      | Controls ($n = 10$) | PCOS ($n = 12$) | $p$-value |
|----------------------|---------------------|-----------------|-----------|
| Age (year)           | 25.26 ± 2.0         | 28.27 ± 1.9     | 0.03*     |
| BMI (kg/m$^2$)       | 26.8 ± 2.0          | 29.4 ± 1.6      | 0.07      |
| Waist (cm)           | 81.1 ± 4.5          | 98.8 ± 4.6      | 0.02*     |
| WHR                  | 0.79 ± 0.02         | 0.87 ± 0.02     | 0.15      |
| Testosterone (nmol/L)| 1.05 ± 0.11         | 1.51 ± 0.23     | 0.08      |
| FAI                  | 2.1 ± 0.65          | 6.77 ± 0.84     | 2.1 × 10$^{-3}$* |
| SHBG (mmol/L)        | 69.6 ± 9.4          | 26 ± 5.1        | 3.2 × 10$^{-3}$* |
| TC (mmol/L)          | 4.61 ± 0.24         | 4.13 ± 0.19     | 0.27      |
| TG (mmol/L)          | 0.84 ± 0.06         | 1.25 ± 0.21     | 0.18      |
| HDL-c (mmol/L)       | 1.48 ± 0.15         | 1.12 ± 0.06     | 0.14      |
| LDL-c (mmol/L)       | 2.66 ± 0.18         | 2.33 ± 0.15     | 0.43      |
| FPG (mmol/L)         | 4.89 ± 0.18         | 4.94 ± 0.16     | 0.97      |
| HbA1c (mmol/mmol/L)  | 33 ± 1.8            | 34 ± 0.84       | 1         |
| TSH (u/L)            | 1.9 ± 0.29          | 1.6 ± 0.17      | 0.59      |
| HOMA-IR              | 1.34 (0.80, 2.13)   | 2.3 (1.3, 3.9)  | 0.04*     |
| VO2 max (ml/kg/min)  | 36.3 ± 2.0          | 26.9 ± 1.40     | 5.6 × 10$^{-3}$* |

*Significantly relevant data.
**TABLE 2** | Differences in amino acids levels before and after exercise between PCOS and healthy controls.

|        | Control | PCOS | P-value | Control | PCOS | P-value |
|--------|---------|------|---------|---------|------|---------|
|        | Mean (SD) | Mean (SD) |         | Mean (SD) | Mean (SD) |         |
| Arginine | 77.85 (16.58) | 80.17 (16.33) | 0.66 | 83.8 (18.32) | 78.96 (17.76) | 0.39 |
| Glutamate | 524.08 (61.14) | 607.64 (102.77) | <0.01 | 557.1 (94.16) | 587.05 (102.84) | 0.33 |
| Histidine | 75.31 (12.23) | 75.79 (9.06) | 0.87 | 79.96 (13.81) | 78.93 (10.98) | 0.79 |
| Methionine | 28.68 (3.91) | 33.74 (5.55) | <0.001 | 31.16 (13.11) | 34.07 (22.18) | 0.16 |
| Ornithine | 44.78 (10.45) | 54.98 (17.86) | 0.01 | 46.93 (13.11) | 52.33 (22.18) | 0.16 |
| Phenylyalanine | 48.95 (6.78) | 53.66 (8.84) | 0.04 | 52.16 (10.87) | 56.44 (10.95) | 0.21 |
| Threonine | 113.25 (29.02) | 128.24 (28.43) | 0.07 | 122.62 (36.26) | 140.01 (39.74) | 0.15 |
| Tyrosine | 66.4 (7.83) | 70.57 (9.9) | 0.1 | 68.78 (12.18) | 70.48 (8.69) | 0.6 |
| Tryptophan | 55.58 (12.1) | 66.91 (17.03) | 0.01 | 58.33 (14.78) | 65.64 (20.97) | 0.2 |
| Valine | 203.88 (44.51) | 227.89 (56.71) | 0.1 | 223.05 (52.65) | 234.73 (65.94) | 0.53 |
| C2acylcarnitine | 4.603 (1.271) | 4.71 (1.216) | 0.1 | 4.787 (1.212) | 5.033 (1.647) | 0.59 |
| C3acylcarnitine | 0.317 (0.061) | 0.341 (0.084) | 0.03 | 0.327 (0.062) | 0.349 (0.084) | 0.33 |
| C5acylcarnitine | 0.123 (0.129) | 0.117 (0.124) | 0.33 | 0.123 (0.107) | 0.126 (0.118) | 0.52 |
| MEDIAN (RANGE) | | | | | | |
| Glycine | 240.5 (266.0) | 273.0 (655.0) | 0.32 | 228.0 (387.0) | 270.0 (240.0) | 0.37 |
| Proline | 120.5 (133.3) | 144.5 (160.8) | 0.05 | 127.0 (133.0) | 157.5 (169.1) | 0.31 |
| Serine | 94.5 (82.4) | 95.0 (115.6) | 0.52 | 93.7 (100.2) | 100.5 (65.0) | 0.6 |

**TABLE 3** | Differences in amino acids levels before and after exercise between PCOS and healthy controls under acute IR induced by lipid infusion.

|        | Control | PCOS | P-value | Control | PCOS | P-value |
|--------|---------|------|---------|---------|------|---------|
|        | Mean (SD) | Mean (SD) |         | Mean (SD) | Mean (SD) |         |
| Arg | 0.94 (0.15) | 0.9 (0.17) | 0.498 | 0.85 (0.14) | 0.97 (0.15) | 0.08 |
| Gin | 1.06 (0.12) | 1.01 (0.12) | 0.236 | 1.01 (0.17) | 1.06 (0.16) | 0.46 |
| Gly | 0.89 (0.09) | 0.82 (0.12) | 0.103 | 0.83 (0.12) | 0.85 (0.12) | 0.67 |
| His | 0.96 (0.11) | 0.9 (0.12) | 0.263 | 0.89 (0.16) | 0.92 (0.11) | 0.66 |
| Met | 0.82 (0.10) | 0.74 (0.12) | 0.110 | 0.74 (0.14) | 0.83 (0.15) | 0.17 |
| Orn | 0.95 (0.21) | 0.87 (0.17) | 0.323 | 0.88 (0.16) | 0.85 (0.20) | 0.72 |
| Phe | 0.84 (0.09) | 0.79 (0.11) | 0.192 | 0.78 (0.10) | 0.84 (0.13) | 0.30 |
| Pro | 0.91 (0.09) | 0.83 (0.08) | 0.015 | 0.82 (0.09) | 0.84 (0.12) | 0.79 |
| Ser | 0.93 (0.09) | 0.87 (0.12) | 0.164 | 0.89 (0.16) | 0.89 (0.11) | 0.99 |
| Thr | 0.90 (0.08) | 0.86 (0.13) | 0.365 | 0.84 (0.11) | 0.87 (0.12) | 0.48 |
| Trp | 0.84 (0.12) | 0.84 (0.08) | 0.885 | 0.61 (0.11) | 0.70 (0.11) | 0.07 |
| Tyr | 0.80 (0.07) | 0.76 (0.11) | 0.199 | 0.76 (0.09) | 0.82 (0.14) | 0.25 |
| Val | 0.96 (0.09) | 0.9 (0.14) | 0.179 | 0.89 (0.13) | 0.94 (0.14) | 0.40 |
| xLeu | 0.93 (0.10) | 0.85 (0.15) | 0.126 | 0.82 (0.12) | 0.91 (0.16) | 0.17 |

1.61 ± 0.75 mg/kg/min, p = 0.01, and controls (glucose disposal mg/kg/min: controls pre-exercise 2.51 ± 1.55; post-exercise 3.01 ± 1.35; p = 0.01). The glucose disposal rate was significantly compromised in PCOS in comparison with healthy controls for both saline and lipid infusions, independent of the exercise.

The endurance exercise for 8 weeks improved cardiovascular fitness in both PCOS patients (mean VO₂ max ml/kg/min ± SEM: before 8 weeks exercise, 26.9 ± 1.40; after 8 weeks exercise, 28.7 ± 1.7, p = 0.05) and controls (mean VO₂ max ml/kg/min ± SEM: before 8 week exercise, 36.3 ± 2.02; after 8 week exercise, 39.2 ± 1.8; p = 0.008). The cardiovascular fitness remained significantly compromised in PCOS in comparison with the controls, even after the exercises driven improvement. Other demographic or biochemical data were not significantly different between the groups after exercise (Table 6).
### TABLE 4 | Assessment of amino acid differences in PCOS and healthy controls before and after exercise.

| Amino Acid | Control Before Exercise | Control After Exercise | P-value | PCOS Before Exercise | PCOS After Exercise | P-value |
|------------|-------------------------|------------------------|---------|----------------------|---------------------|---------|
| Arginine   | 77.85 (16.58)           | 83.8 (18.32)           | 0.265   | 80 (17.63)           | 78.96 (17.76)       | 0.838   |
| Glutamate  | 524.08 (61.14)          | 557.1 (94.16)          | 0.169   | 607.64 (102.77)      | 587.05 (102.84)     | 0.485   |
| Histidine  | 75.31 (12.23)           | 79.96 (13.81)          | 0.243   | 75.79 (9.06)         | 78.93 (10.98)       | 0.273   |
| Methionine | 28.68 (3.91)            | 31.16 (7.07)           | 0.173   | 33.74 (5.55)         | 34.07 (6.14)        | 0.843   |
| Ornithine  | 44.78 (10.45)           | 46.93 (13.11)          | 0.55    | 54.98 (17.86)        | 52.33 (22.18)       | 0.642   |
| Phelyalanine| 48.95 (6.78)            | 52.16 (10.87)          | 0.24    | 53.66 (8.84)         | 56.44 (10.95)       | 0.325   |
| Threonine  | 113.25 (29.02)          | 122.62 (36.26)         | 0.347   | 128.24 (28.43)       | 140.01 (39.74)      | 0.248   |
| Tyrosine   | 66.4 (7.83)             | 68.78 (12.16)          | 0.438   | 70.57 (9.9)          | 70.48 (6.69)        | 0.974   |
| Valine     | 203.88 (44.51)          | 223.05 (52.66)         | 0.197   | 227.89 (56.71)       | 234.73 (65.94)      | 0.695   |
| xLeucine   | 164.29 (31.61)          | 180.9 (47.16)          | 0.171   | 185.96 (38.23)       | 196.23 (51.49)      | 0.422   |
| C2acylcarnitine | 4.603 (1.271)     | 4.787 (1.212)          | 0.629   | 4.71 (1.216)         | 5.033 (1.647)       | 0.429   |
| C3acylcarnitine | 0.317 (0.061)         | 0.327 (0.062)          | 0.597   | 0.341 (0.084)        | 0.349 (0.084)       | 0.736   |
| C5acylcarnitine | 0.123 (0.129)         | 0.123 (0.107)          | 0.636   | 0.117 (0.124)        | 0.126 (0.118)       | 0.292   |

### TABLE 5 | Assessment of amino acid differences in PCOS and healthy controls before and after exercise under acute IR induced by lipid infusion.

| Amino Acid | Control Before Exercise | Control After Exercise | P-value | PCOS Before Exercise | PCOS After Exercise | P-value |
|------------|-------------------------|------------------------|---------|----------------------|---------------------|---------|
| Arg        | 0.94 (0.15)             | 0.85 (0.14)            | 0.149   | 0.9 (0.17)           | 0.97 (0.15)         | 0.305   |
| Gin        | 1.06 (0.12)             | 1.01 (0.17)            | 0.393   | 1.01 (0.12)          | 1.06 (0.16)         | 0.316   |
| Gly        | 0.89 (0.09)             | 0.83 (0.12)            | 0.161   | 0.82 (0.12)          | 0.85 (0.12)         | 0.574   |
| His        | 0.96 (0.11)             | 0.89 (0.16)            | 0.270   | 0.9 (0.12)           | 0.92 (0.11)         | 0.763   |
| Met        | 0.82 (0.10)             | 0.74 (0.14)            | 0.142   | 0.74 (0.12)          | 0.83 (0.15)         | 0.131   |
| Orn        | 0.95 (0.21)             | 0.88 (0.16)            | 0.381   | 0.87 (0.17)          | 0.85 (0.20)         | 0.718   |
| Phe        | 0.84 (0.09)             | 0.78 (0.10)            | 0.147   | 0.79 (0.11)          | 0.84 (0.13)         | 0.349   |
| Pro        | 0.91 (0.09)             | 0.82 (0.09)            | 0.031   | 0.83 (0.08)          | 0.84 (0.12)         | 0.775   |
| Ser        | 0.93 (0.09)             | 0.89 (0.16)            | 0.428   | 0.87 (0.12)          | 0.89 (0.11)         | 0.711   |
| Thr        | 0.90 (0.08)             | 0.84 (0.11)            | 0.152   | 0.86 (0.13)          | 0.87 (0.12)         | 0.773   |
| Trp        | 0.64 (0.12)             | 0.61 (0.11)            | 0.500   | 0.64 (0.08)          | 0.70 (0.11)         | 0.099   |
| Tyr        | 0.80 (0.07)             | 0.76 (0.09)            | 0.195   | 0.76 (0.11)          | 0.82 (0.14)         | 0.213   |
| Val        | 0.96 (0.09)             | 0.89 (0.13)            | 0.190   | 0.9 (0.14)           | 0.94 (0.14)         | 0.413   |
| xLeu       | 0.93 (0.10)             | 0.82 (0.12)            | 0.031   | 0.85 (0.15)          | 0.91 (0.16)         | 0.352   |

### DISCUSSION

The aim of this study was to determine whether moderate exercise would contribute to the overall improvement in metabolism of PCOS and healthy controls. We found significant differences in the levels of amino acids distinguishing PCOS and control at baseline, which were not present after the exercise, suggesting improvement of the overall metabolism in PCOS individuals. However, while comparing the levels of amino acids before and after exercise within the groups at the baseline there were no differences. The glucose disposal rate and cardiovascular fitness were significantly improved by the exercise.

The comorbidities associated with PCOS include IR, T2D, obesity, and risk of cardiovascular complications (6, 33–35). Those complex diseases manifest alterations in the metabolic profile in comparison with healthy individuals (15, 17, 31); similarly, deregulated metabolism was also observed in women with PCOS (20, 21, 24). The metabolic alterations in the levels...
of ornithine, phenylalanine, tyrosine, and leucine observed in our study in PCOS at the baseline are in agreement with a previous report (23) further confirming deregulated metabolism in PCOS patients. Increases in the levels of circulating BCAA and AAA were associated with obesity, worse metabolic health followed by future insulin resistance and/or T2D (36). Moreover, BCAA and AAA were recognized as predictors of T2D risk (37), which might potentially contribute to the development of IR via activation of mammalian target of rapamycin complex 1 (mTORC1) and suppression of mitochondrial function in beta-cells (36). Importantly, insulin infusion under euglycemia was shown to decrease levels of BCAA and AAA suggesting a cross-talk between both pathways (38). Thus, elevated levels of BCAA and AAA observed in our study in PCOS suggest their poor metabolic health, which further might lead to IR and T2D. Noteworthy, the elevated levels of BCAA and AAA might potentially reflect compromised GDR, which we observed in PCOS in comparison with healthy control.

We conducted lipid infusions to simulate acute IR and monitor metabolic deregulations under such conditions. Although the lipid infusion significantly altered levels of numbers of acetylcarnitines and lysophospholipides (as we demonstrated on OPLS), the level of BCAA was not affected and among AAA only tryptophan was altered. Elevated levels of long chain carnitines after the lipid infusion might suggest increased fatty acid oxidation required for the energy generation. Furthermore, an elevated level of acetylcarnitine, a product of beta-oxidation of fatty acid further suggests upregulation of this pathway under the lipid infusion. A causative role of tryptophan in fatty acid and triglyceride metabolism was previously reported (39), here we confirm the crosstalk between the pathways and suggest that lipid metabolism is impacting on the tryptophan level in both PCOS and healthy controls.

The improvement in IS in both controls and PCOS after the course of the exercise, which we observed is in agreement with previous studies reporting on exercise-driven improvements in IS in T2D and PCOS (9–11, 13, 40). Moreover, it was shown that the exercise improved the overall glucose homeostasis and lipid metabolism (41, 42) potentially via acceleration of mitochondrial capacity as well as improvement of glucose transport through GLUT4 in muscles (42). In our study, after 8 weeks of exercise the significant differences in the levels of amino acids seen between PCOS and controls at baseline were no longer apparent. The BCAA metabolism contributes to mitochondrial respiration, thus improvement of overall mitochondrial capacity potentially caused by the exercise could further contribute to the normalization of BCAA metabolism in our study. However, we did not observe a significant difference in metabolic levels within the group (PCOS, control) after testing for significance before and after exercise. This could be due the small group of individuals enrolled for this study, given the metabolic heterogeneity, previously reported in women with PCOS (20). Because moderate exercise could contribute to the overall improvement of body metabolism, as the PCOS amino acid profile did not differ to control, a further study with a larger number of individuals would delineate the interplay between moderate exercises, IR and amino acid metabolism.

Exercise increased VO2 max and increased IS as expected, with an exaggeration of IR following the acute lipid infusion indicating that the lipid infusion technique may be of value to modulate insulin resistance directly to assess its metabolic impact, rather than the more common situation of interventions to reduce IR therapeutically. The acute increase in IR from the lipid infusion likely results from an acute rise in diacylglycerol (DAG) in the muscle that subsequently induces insulin resistance by reducing non-oxidative glucose disposal through PKCθ activation (25). Following exercise, the improvement in IS was likely due to increased fat oxidation with moderate intensity exercise (40), and a reduction in intra-myocellular fat metabolites would improve IR (13); notably, IS did not reverse entirely to that of the control subjects, indicative of the underlying metabolic defect in PCOS (35). However, this study suggests that PCOS women who undertake moderate intensity exercise for 180 min per week without weight loss may address their metabolic differences and reduce their IR.

The strengths of this study were using gold standard methodology for this intensive interventional study, the well supervised exercise intervention and the state-of-the-art
metabolomics analysis available to us. The limitations were that this was a small group of women with PCOS, though all fulfilled all three of the diagnostic criteria for its diagnosis thereby reducing heterogeneity, and the groups were not well matched for BMI and age.

In summary, the baseline amino acid profile in PCOS reflected that seen in obese non-PCOS subjects and was reversed to that seen in controls by exercise without a change in weight, in association with an increase in IS. This shows that exercise may normalize the amino acid metabolome irrespective of weight. Nevertheless, a study focusing on a larger number of individuals would be required to provide further insights in PCOS metabolism in the context of physical activity.

ETHICS STATEMENT

All patients provided written informed consent to participate in the study, which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. This study was approved by the Leeds Central Research Ethics Committee, and was approved by the Leeds Central Research Ethics Committee, Declaration of Helsinki and Good Clinical Practice. This study in the study, which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All patients provided written informed consent to participate.

AUTHOR CONTRIBUTIONS

SA devised the study that was undertaken by MA. MK and AH conducted the measurements. AH and KS were responsible for the metabolic analysis and SD undertook the statistical analysis. All authors contributed to the writing of the manuscript.

ACKNOWLEDGMENTS

This work was part of an MD thesis and its publishing is in line with the University of Hull policy, and can be accessed online https://hydra.hull.ac.uk/assets/hull:8395a/content online (33).

We are grateful for infrastructure support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine-Qatar. The publication of this article was funded by the Qatar National Library.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2019.00116/full#supplementary-material

REFERENCES

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. (2004) 89:2745–9. doi: 10.1210/jc.2003-020246
2. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. (2018) 110:364–79. doi: 10.1016/j.fertnstert.2018.05.004
3. Bani Mohammad M, Majdi Seghinsara A. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prev. (2017) 18:17–21. doi: 10.22034/APJCP.2017.18.1.17
4. Rotterdam EA-SPCGG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. (2004) 81:19–25. doi: 10.1016/j.fertnstert.2003.10.004
5. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. (2009) 91:456–88. doi: 10.1016/j.fertnstert.2008.06.035
6. Stepo NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulinaemic clamp. Hum Reprod. (2013) 28:777–84. doi: 10.1093/humrep/des463
7. Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepo NK. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. (2016) 31:2619–31. doi: 10.1093/humrep/dew243
8. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update (2017) 23:171–83. doi: 10.1093/humupd/dmq045
9. Herzig KH, Ahol ST, Leppaluoto J, Jokelainen J, James T, Keinanen-Kiukaanniemi S. Light physical activity determined by a motion sensor decreases insulin resistance, improves lipid homeostasis and reduces visceral fat in high-risk subjects: PreDiabEx study RCT. Int J Obes. (2014) 38:1089–96. doi: 10.1038/ijo.2013.224
10. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. (2008) 93:3373–80. doi: 10.1210/jc.2008-0751
11. Palomba S, Giaiguria F, Falbo A, Russo T, Oppedisano R, Tolino A, et al. Structured exercise training programme versus hypocaloric hyperprotein diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod. (2008) 23:642–50. doi: 10.1093/humrep/dem391
12. Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab. (2006) 31:384–91. doi: 10.1139/h06-007
13. Bruce CR, Thrush AB, Mertz VA, Bezaire V, Chabowski A, Heigenhauser GJ, et al. Endurance training in obese humans improves glucose tolerance and mitochondrial fatty acid oxidation and alters muscle lipid content. *Am J Physiol Endocrinol Metab*. (2006) 291:E99–107. doi: 10.1152/ajpendo.00587.2005

14. Schenk S, Horowitz JF. Acute exercise increases triglyceride synthesis in skeletal muscle and prevents fatty acid-induced insulin resistance. *J Clin Invest*. (2007) 117:1690–8. doi: 10.1172/JCI30566

15. Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. *Cold Spring Harb Mol Case Stud*. (2015) 1:a000588. doi: 10.1101/mcs.a000588

16. Wurtz P, Soininen P, Kangas AJ, Ronnemaa T, Lehtimaki T, Kahonen M, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. *Diabetes Care* (2013) 36:648–55. doi: 10.237/diabetes.2012-0895

17. Newgard CB, An J, Bain JR, Muehlabauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. *Cell Metab*. (2009) 9:311–26. doi: 10.1016/j.cmet.2009.02.002

18. Zhao X, Han Q, Liu Y, Sun C, Gang X, Wang G. The relationship between branched-chain amino acid related metabolic signature and insulin resistance: a systematic review. *J Diabetes Res*. (2016) 2016:2794591. doi: 10.1155/2016/2794591

19. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. *Cell Metab*. (2012) 15:606–14. doi: 10.1016/j.cmet.2012.01.024

20. Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramirez M, Lasuncion MA, et al. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolic approach using GC-MS. *Clin Chem*. (2012) 58:999–1009. doi: 10.1373/clinchem.2011.176396

21. Atiomo W, Daykin CA. Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study. *Mol Hum Reprod*. (2012) 18:546–53. doi: 10.1093/molehr/gas029

22. Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q, et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. *J Proteome Res*. (2012) 11:2937–46. doi: 10.1021/pr3003317

23. Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. *BMC Med*. (2012) 10:153. doi: 10.1186/1741-7015-10-153

24. Chang AY, Lalia AZ, Jenkins GD, Dutta T, Carter RE, Singh RJ, et al. Combining a non-targeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome. *Metabolism* (2017) 71:52–63. doi: 10.1016/j.metabol.2017.03.002

25. Nowotny B, Zahiragic L, Krog D, Nowotny PJ, Herder C, Carstensen M, et al. Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans. *Diabetes* (2013) 62:2240–8. doi: 10.2337/db12-1179

26. Zuniga-Guajardo S, Jimenez J, Angel A, Zinman B, Effects of massive obesity on insulin sensitivity and insulin clearance and the metabolic response to insulin as assessed by the euglycemic clamp technique. *Metabolism* (1986) 35:278–82. doi: 10.1016/0026-0495(86)90214-3

27. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol*. (1979) 237:E214–23.

28. Kuipers H, Verstappen FT, Keizer HA, Geurten P, van Krannenburg G. Variability of aerobic performance in the laboratory and its physiologic correlates. *Int J Sports Med*. (1985) 6:197–201. doi: 10.1055/s-2008-1025839

29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. (1972) 18:499–502.

30. Halama A, Horsch M, Kastenmüller G, Möller G, Kumar P, Prehn C, et al. Metabolic switch during adipogenesis: from branched chain amino acid catabolism to lipid synthesis. *Arch Biochem Biophys*. (2016) 589:93–107. doi: 10.1016/j.abb.2015.09.013

31. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C, et al. A genome-wide perspective of genetic variation in human metabolism. *Nat Genet*. (2010) 42:137–41. doi: 10.1038/ng.507

32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* (1985) 28:412–9. doi: 10.1007/BF00280883

33. Aye MM. Effect of Non-esterified Fatty Acids on Insulin Resistance and Cardiovascular Risk in Polycystic Ovary Syndrome. Doctoral dissertation, University of Hull and University of York (2013).

34. Ehrmann DA. Insulin resistance and polycystic ovary syndrome. *Curr Diab Rep*. (2002) 2:71–6. doi: 10.1017/s11892-006-1

35. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). *Am J Physiol Endocrinol Metab*. (2001) 281:E392–9. doi: 10.1152/ajpendo.2001.281.2.E392

36. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. *Nat Rev Endocrinol*. (2014) 10:723–36. doi: 10.1038/nrendo.2014.171

37. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolic profiles and the risk of developing diabetes. *Nat Med*. (2011) 17:448–53. doi: 10.1038/nm.2307

38. Halama A, Kahal H, Bhagwat AM, Zierer J, Sathyapalan T, Graumann J, et al. Metabolic and proteomic signatures of hypoglycaemia in type 2 diabetes. *Diabetes Obes Metab*. (2018). doi: 10.1111/dom.13602. [Epub ahead of print]

39. Fears R, Murrell EA. Tryptophan and the control of triglyceride and carbohydrate metabolism in the rat. *Br J Nutr*. (1980) 43:349–56.

40. Romijn JA, Coyle EF, Siddis LS, Gastaldelli A, Horowitz JF, Endert E, et al. Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. *Am J Physiol*. (1993) 265 (3 Pt 1):E380–91.

41. Verducci E, Lassandro C, Giaichero R, Miniello VL, Banderali G, Radaelli G. Change in metabolic profile after 1-year nutritional-behavioral intervention in obese children. *Nutrients* (2015) 7:10089–99. doi: 10.3390/nu7125520

42. Mul JD, Stanford KL, Hirshman MF, Goodyear LJ. Exercise and regulation of carbohydrate metabolism. *Prog Mol Biol Transl Sci*. (2015) 135:17–37. doi: 10.1016/bs.pmbts.2015.07.020

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Halama, Aye, Dargham, Kulinski, Sahure and Atkin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.